



- (51) **International Patent Classification:**
A01N 43/30 (2006.01) *A61K 31/36* (2006.01)
- (21) **International Application Number:**
 PCT/US2012/050268
- (22) **International Filing Date:**
 10 August 2012 (10.08.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
 61/525,440 19 August 2011 (19.08.2011) US
 61/650,681 23 May 2012 (23.05.2012) US
- (71) **Applicant** (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; c/o GlaxoSmithKline, Global Patents Department, Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).
- (72) **Inventors; and**
- (75) **Inventors/Applicants** (for US only): **CHONG, Pek Yoke** [US/US]; c/o GlaxoSmithKline, Global Patents Department, Five Moore Drive P. O. Box 13398, Research Triangle Park, North Carolina 27709 (US). **MILLER, John F.** [US/US]; c/o GlaxoSmithKline, Global Patents Department, Five Moore Drive, P. O. Box 13398, Research Triangle Park, North Carolina 27709 (US). **PEAT, Andrew James** [US/US]; c/o GlaxoSmithKline, Global Patents Department, Five Moore Drive P. O. Box 13398, Research Triangle Park, North Carolina 27709 (US). **SHOTWELL, John Brad** [US/US]; c/o GlaxoSmithKline, Global Patents Department, Five Moore Drive P. O. Box 13398, Research Triangle Park, NC 27709 (US).
- (74) **Agent:** **LEMANOWICZ, John L.**; c/o GlaxoSmithKline, Global Patents Department, Five Moore Drive, P.O.Box 13398, Research Triangle Park, NC 27709 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) **Title:** BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS



(57) **Abstract:** The present invention features compounds of formula (I) and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.